SI
SI
discoversearch

Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
183 49 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
183Thnx, indeed very good results for small # subjects enrolled. CRs after Rituxan Miljenko Zuanic-last Thursday
182Could this be the institutional recreation to 47 data? d18rn0p25nwr6d.cloudfronsemi_infinite -last Thursday
181Competitor 47 out with good ASCO data: Forty Seven P1/2 data Cheers, Tucktuck-last Thursday
180I took bite size chunks when it dropped below $6 recently. It seems the probabisemi_infinite -last Tuesday
179I have bought a little more over the last few weeks. Breaking the T-cell group iBiomaven-last Tuesday
178Peter et. al., Are any of you buying more here? BladerunnerBladerunner17-last Tuesday
177While Nic sits there with thumb up butt...... healio.com DLBCL and follicular scaram(o)uche-May 4
176MC of ~376M and EV of ~290M at current share price. TRIL gets no respect. :-semi_infinite -April 19
175Surface Oncology (SURF) IPO priced at high end of range. Cheers, Tucktuck-April 19
174List of CD47 programs by an unknown Trillium long, with some reasonably balancedtuck1April 5
173>> Another competitor that is no longer preclinical << Not a problescaram(o)uche-April 5
172 That's OK, as I've heard that Nic is developing a secret weapon (IgG3 cscaram(o)uche1April 5
171Another competitor that is no longer preclinical: SRF231 now in P1 Surface notuck-April 5
170Boehringer nabs OSE's preclinical SIRP-alpha immuno-oncology drug http://wwscaram(o)uche-April 4
169<TTI-622, an IgG4 SIRPaFc protein which is primarily being developed for combMiljenko Zuanic1March 16
168Does TTI-622 (relative to 621) have option for less frequent dosing (IgG4 ve IgGMiljenko Zuanic-March 15
167TRIL reports 2017 results Trillium Therapeutics Reports Annual 2017 FinanBladerunner17-March 9
166OT re garbled links: Old SI problem. The links have to be pasted because of thetuck-February 22
165 Wow. Don't know why the link gets garbled. Same thing goes for the searchscaram(o)uche-February 21
164Authors all from Trillium ("triggers CD47-mediated tumor cell apoptosis&quoscaram(o)uche-February 21
163 Overexpression of CD47 involved in abdominal aortic aneurysms scopeblog.stanforBulbaMan-February 17
162 I am not a subscriber to Sally's Blog, biotechstrategyblog.com , though I&#ghmm-February 7
161 Janus Capital files, indicating that they've dropped below 5% ownership. Lscaram(o)uche-February 6
160 Same idea, different combo on mice. med.stanford.edusemi_infinite -February 4
159<Might be you really do need to get to close to 100% receptor occupancy to reMiljenko Zuanic1February 4
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.